^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    hydroxychloroquine

    Company:
    Generic mfg.
    Drug class:
    Immunomodulator, PLA2 inhibitor
    Related drugs:
    1d
    APLAQUINE: Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome (clinicaltrials.gov)
    P2, N=25, Completed, University Hospital, Rouen | Unknown status --> Completed
    Trial completion
    |
    hydroxychloroquine
    2d
    Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    gemcitabine • docetaxel • hydroxychloroquine
    3d
    A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration (clinicaltrials.gov)
    P1/2, N=57, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2030 --> Mar 2026 | Trial primary completion date: Mar 2027 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    BRAF V600E • BRAF V600 • BRAF fusion
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine
    6d
    Study on the Efficacy and Safety of Short-Course Telitacicept in Sjögren's Syndrome (ChiCTR2600117190)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University
    New trial
    |
    hydroxychloroquine
    6d
    A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR2500107574)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • hydroxychloroquine • tofacitinib • CBT-1 (tetrandrine)
    7d
    Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. (PubMed, J Immunother Cancer)
    REVOLUTION cohorts A and B demonstrated encouraging antitumor activity in patients with mPDAC. In cohort B, hydroxychloroquine-related tolerability issues contributed to early discontinuations and reduced drug exposure. These findings highlight the potential and limitations of current chemoimmunotherapy approaches. Although neither cohort will be expanded, the results reinforce the continued promise of chemoimmunotherapy in mPDAC and the importance of refining these strategies.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • albumin-bound paclitaxel • hydroxychloroquine
    14d
    Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=10, Completed, Emory University | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • albumin-bound paclitaxel • hydroxychloroquine
    17d
    Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov)
    P4, N=10, Not yet recruiting, University of California, San Francisco
    New P4 trial
    |
    5-fluorouracil • Jakafi (ruxolitinib) • hydroxychloroquine • tofacitinib • Cosentyx (secukinumab) • Dupixent (dupilumab) • Ilumya (tildrakizumab-asmn)
    18d
    When Immunosuppression Fails: Cardiac Myxoma Mimicking Systemic Lupus Erythematosus Flare With a Diagnostic Delay. (PubMed, Cureus)
    During this period, she received escalating immunosuppression with corticosteroids, mycophenolate, and cyclophosphamide...Immunosuppression was de-escalated to hydroxychloroquine alone with no recurrence at 14-month follow-up...Cardiac myxomas produce IL-6 in the majority of patients (frequency >75%), and systemic constitutional signs are observed in a substantial proportion, though not uniformly. This can produce IL-6-mediated inflammation indistinguishable from autoimmune flares.
    Journal
    |
    IL6 (Interleukin 6)
    |
    cyclophosphamide • hydroxychloroquine
    22d
    The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (clinicaltrials.gov)
    P=N/A, N=186, Not yet recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    hydroxychloroquine • tofacitinib
    29d
    The Dual Role of Autophagy in Lung Cancer: From Molecular Mechanisms to Metabolic Regulation and Targeted Therapy Strategies. (PubMed, Front Biosci (Landmark Ed))
    In addition, we critically appraise clinical attempts to modulate autophagy (e.g., with chloroquine/hydroxychloroquine (CQ/HCQ) or mTOR inhibitors), outlining reasons for mixed outcomes and proposing practical solutions for future trials. Finally, potential targeted therapeutic strategies are discussed, including approaches to inhibit cytoprotective autophagy and strategies to induce autophagy-dependent cell death using novel small-molecule activators. Collectively, the evidence supports a model in which precise, context-aware modulation of autophagy-guided by pharmacodynamic (PD) biomarkers and molecular stratification-will be key to improving outcomes in lung cancer.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • STK11 (Serine/threonine kinase 11) • BECN1 (Beclin 1)
    |
    hydroxychloroquine
    1m
    Efficacy and Safety of Different Dose Regimens of Gabapentin for Treating Erythema/Flushing in Rosacea: A Randomized Controlled Trial (clinicaltrials.gov)
    P1, N=50, Completed, First Affiliated Hospital of Chongqing Medical University | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    hydroxychloroquine